{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T23:06:36Z","timestamp":1773270396111,"version":"3.50.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,7,14]],"date-time":"2010-07-14T00:00:00Z","timestamp":1279065600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Med Genet"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1186\/1471-2350-11-111","type":"journal-article","created":{"date-parts":[[2010,7,14]],"date-time":"2010-07-14T18:13:53Z","timestamp":1279131233000},"source":"Crossref","is-referenced-by-count":43,"title":["Genetic polymorphisms in MDR1, CYP3A4 and CYP3A5 genes in a Ghanaian population: a plausible explanation for altered metabolism of ivermectin in humans?"],"prefix":"10.1186","volume":"11","author":[{"given":"William","family":"Kudzi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander NO","family":"Dodoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy J","family":"Mills","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,7,14]]},"reference":[{"issue":"11","key":"672_CR1","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.1021\/bi972709x","volume":"37","author":"CG Lee","year":"1998","unstructured":"Lee CG, Gottesman MM, Cardarelli CO, Ramachandra M, Jeang KT, Ambudkar SV, Pastan I, Dey S: HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry. 1998, 37 (11): 3594-3601. 10.1021\/bi972709x.","journal-title":"Biochemistry"},{"key":"672_CR2","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1146\/annurev.pharmtox.43.100901.140233","volume":"43","author":"M Schwab","year":"2003","unstructured":"Schwab M, Eichelbaum M, Fromm MF: Genetic polymorphisms of the human MDR1 drug transporter. Annu Rev Pharmacol Toxicol. 2003, 43: 285-307. 10.1146\/annurev.pharmtox.43.100901.140233.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"2","key":"672_CR3","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1073\/pnas.86.2.695","volume":"86","author":"C Cordon-Cardo","year":"1989","unstructured":"Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, Bertino JR: Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA. 1989, 86 (2): 695-698. 10.1073\/pnas.86.2.695.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"672_CR4","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/BF00160054","volume":"26","author":"A MacFarland","year":"1994","unstructured":"MacFarland A, Abramovich DR, Ewen SW, Pearson CK: Stage-specific distribution of P-glycoprotein in first-trimester and full-term human placenta. Histochem J. 1994, 26 (5): 417-423. 10.1007\/BF00160054.","journal-title":"Histochem J"},{"issue":"21","key":"672_CR5","doi-asserted-by":"publisher","first-page":"7735","DOI":"10.1073\/pnas.84.21.7735","volume":"84","author":"F Thiebaut","year":"1987","unstructured":"Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC: Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA. 1987, 84 (21): 7735-7738. 10.1073\/pnas.84.21.7735.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"672_CR6","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1517\/phgs.4.4.397.22747","volume":"4","author":"T Sakaeda","year":"2003","unstructured":"Sakaeda T, Nakamura T, Okumura K: Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics. 2003, 4 (4): 397-410. 10.1517\/phgs.4.4.397.22747.","journal-title":"Pharmacogenomics"},{"issue":"7","key":"672_CR7","doi-asserted-by":"publisher","first-page":"3473","DOI":"10.1073\/pnas.97.7.3473","volume":"97","author":"S Hoffmeyer","year":"2000","unstructured":"Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, et al: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA. 2000, 97 (7): 3473-3478. 10.1073\/pnas.050585397.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"672_CR8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.clpt.2003.09.012","volume":"75","author":"C Marzolini","year":"2004","unstructured":"Marzolini C, Paus E, Buclin T, Kim RB: Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther. 2004, 75 (1): 13-33. 10.1016\/j.clpt.2003.09.012.","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"672_CR9","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1023\/A:1020433422259","volume":"19","author":"M Horinouchi","year":"2002","unstructured":"Horinouchi M, Sakaeda T, Nakamura T, Morita Y, Tamura T, Aoyama N, Kasuga M, Okumura K: Significant genetic linkage of MDR1 polymorphisms at positions 3435 and 2677: functional relevance to pharmacokinetics of digoxin. Pharm Res. 2002, 19 (10): 1581-1585. 10.1023\/A:1020433422259.","journal-title":"Pharm Res"},{"issue":"8","key":"672_CR10","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1097\/00008571-200308000-00006","volume":"13","author":"DL Kroetz","year":"2003","unstructured":"Kroetz DL, Pauli-Magnus C, Hodges LM, Huang CC, Kawamoto M, Johns SJ, Stryke D, Ferrin TE, DeYoung J, Taylor T, et al: Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics. 2003, 13 (8): 481-494. 10.1097\/00008571-200308000-00006.","journal-title":"Pharmacogenetics"},{"issue":"1","key":"672_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00008571-199602000-00002","volume":"6","author":"DR Nelson","year":"1996","unstructured":"Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, et al: P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics. 1996, 6 (1): 1-42. 10.1097\/00008571-199602000-00002.","journal-title":"Pharmacogenetics"},{"issue":"8-9","key":"672_CR12","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1080\/00498250110060969","volume":"31","author":"A Ayrton","year":"2001","unstructured":"Ayrton A, Morgan P: Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica. 2001, 31 (8-9): 469-497. 10.1080\/00498250110060969.","journal-title":"Xenobiotica"},{"issue":"1","key":"672_CR13","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0022-3565(25)22379-5","volume":"270","author":"T Shimada","year":"1994","unstructured":"Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP: Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther. 1994, 270 (1): 414-423.","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"672_CR14","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/86882","volume":"27","author":"P Kuehl","year":"2001","unstructured":"Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, et al: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001, 27 (4): 383-391. 10.1038\/86882.","journal-title":"Nat Genet"},{"issue":"3","key":"672_CR15","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/S0022-3565(24)37149-6","volume":"283","author":"MF Paine","year":"1997","unstructured":"Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, Perkins JD, Thummel KE: Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther. 1997, 283 (3): 1552-1562.","journal-title":"J Pharmacol Exp Ther"},{"issue":"10","key":"672_CR16","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1124\/dmd.30.10.1108","volume":"30","author":"I Koch","year":"2002","unstructured":"Koch I, Weil R, Wolbold R, Brockmoller J, Hustert E, Burk O, Nuessler A, Neuhaus P, Eichelbaum M, Zanger U, et al: Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab Dispos. 2002, 30 (10): 1108-1114. 10.1124\/dmd.30.10.1108.","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"672_CR17","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1080\/004982598239597","volume":"28","author":"Z Zeng","year":"1998","unstructured":"Zeng Z, Andrew NW, Arison BH, Luffer-Atlas D, Wang RW: Identification of cytochrome P4503A4 as the major enzyme responsible for the metabolism of ivermectin by human liver microsomes. Xenobiotica. 1998, 28 (3): 313-321. 10.1080\/004982598239597.","journal-title":"Xenobiotica"},{"issue":"10","key":"672_CR18","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/S0169-409X(02)00066-2","volume":"54","author":"JK Lamba","year":"2002","unstructured":"Lamba JK, Lin YS, Schuetz EG, Thummel KE: Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev. 2002, 54 (10): 1271-1294. 10.1016\/S0169-409X(02)00066-2.","journal-title":"Adv Drug Deliv Rev"},{"issue":"16","key":"672_CR19","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1093\/jnci\/90.16.1225","volume":"90","author":"TR Rebbeck","year":"1998","unstructured":"Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz SB: Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst. 1998, 90 (16): 1225-1229. 10.1093\/jnci\/90.16.1225.","journal-title":"J Natl Cancer Inst"},{"issue":"22","key":"672_CR20","doi-asserted-by":"publisher","first-page":"13176","DOI":"10.1073\/pnas.95.22.13176","volume":"95","author":"CA Felix","year":"1998","unstructured":"Felix CA, Walker AH, Lange BJ, Williams TM, Winick NJ, Cheung NK, Lovett BD, Nowell PC, Blair IA, Rebbeck TR: Association of CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci USA. 1998, 95 (22): 13176-13181. 10.1073\/pnas.95.22.13176.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"672_CR21","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1097\/00008571-200107000-00008","volume":"11","author":"R Eiselt","year":"2001","unstructured":"Eiselt R, Domanski TL, Zibat A, Mueller R, Presecan-Siedel E, Hustert E, Zanger UM, Brockmoller J, Klenk HP, Meyer UA, et al: Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics. 2001, 11 (5): 447-458. 10.1097\/00008571-200107000-00008.","journal-title":"Pharmacogenetics"},{"issue":"2","key":"672_CR22","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1161\/01.HYP.0000151361.31736.96","volume":"45","author":"H Ho","year":"2005","unstructured":"Ho H, Pinto A, Hall SD, Flockhart DA, Li L, Skaar TC, Cadman P, O'Connor DT, Wagner U, Fineberg NS, et al: Association between the CYP3A5 genotype and blood pressure. Hypertension. 2005, 45 (2): 294-298. 10.1161\/01.HYP.0000151361.31736.96.","journal-title":"Hypertension"},{"key":"672_CR23","volume-title":"Technical Report Series No 852","author":"Control WECoO","year":"1995","unstructured":"Control WECoO: Onchocerciasis and its control. Technical Report Series No 852. 1995"},{"issue":"1-2","key":"672_CR24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ijpharm.2002.12.002","volume":"277","author":"LZ Benet","year":"2004","unstructured":"Benet LZ, Cummins CL, Wu CY: Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. International journal of pharmaceutics. 2004, 277 (1-2): 3-9. 10.1016\/j.ijpharm.2002.12.002.","journal-title":"International journal of pharmaceutics"},{"issue":"1","key":"672_CR25","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1475-2883-2-2","volume":"2","author":"Y Dadzie","year":"2003","unstructured":"Dadzie Y, Neira M, Hopkins D: Final report of the Conference on the eradicability of Onchocerciasis. Filaria J. 2003, 2 (1): 2-10.1186\/1475-2883-2-2.","journal-title":"Filaria J"},{"issue":"3","key":"672_CR26","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1179\/000349804225003253","volume":"98","author":"K Awadzi","year":"2004","unstructured":"Awadzi K, Boakye DA, Edwards G, Opoku NO, Attah SK, Osei-Atweneboana MY, Lazdins-Helds JK, Ardrey AE, Addy ET, Quartey BT, et al: An investigation of persistent microfilaridermias despite multiple treatments with ivermectin, in two onchocerciasis-endemic foci in Ghana. Ann Trop Med Parasitol. 2004, 98 (3): 231-249. 10.1179\/000349804225003253.","journal-title":"Ann Trop Med Parasitol"},{"issue":"4","key":"672_CR27","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1179\/000349804225003442","volume":"98","author":"K Awadzi","year":"2004","unstructured":"Awadzi K, Attah SK, Addy ET, Opoku NO, Quartey BT, Lazdins-Helds JK, Ahmed K, Boatin BA, Boakye DA, Edwards G: Thirty-month follow-up of sub-optimal responders to multiple treatments with ivermectin, in two onchocerciasis-endemic foci in Ghana. Ann Trop Med Parasitol. 2004, 98 (4): 359-370. 10.1179\/000349804225003442.","journal-title":"Ann Trop Med Parasitol"},{"issue":"1","key":"672_CR28","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.molbiopara.2005.05.006","volume":"143","author":"BF Ardelli","year":"2005","unstructured":"Ardelli BF, Guerriero SB, Prichard RK: Genomic organization and effects of ivermectin selection on Onchocerca volvulus P-glycoprotein. Mol Biochem Parasitol. 2005, 143 (1): 58-66. 10.1016\/j.molbiopara.2005.05.006.","journal-title":"Mol Biochem Parasitol"},{"key":"672_CR29","unstructured":"Whatman FTA Protocol. [ http:\/\/www.whatman.com ]"},{"issue":"3","key":"672_CR30","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1067\/mcp.2001.114164","volume":"69","author":"I Cascorbi","year":"2001","unstructured":"Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, Schaeffeler E, Eichelbaum M, Brinkmann U, Roots I: Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther. 2001, 69 (3): 169-174. 10.1067\/mcp.2001.114164.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"672_CR31","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/00008571-200104000-00005","volume":"11","author":"MM Ameyaw","year":"2001","unstructured":"Ameyaw MM, Regateiro F, Li T, Liu X, Tariq M, Mobarek A, Thornton N, Folayan GO, Githang'a J, Indalo A, et al: MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics. 2001, 11 (3): 217-221. 10.1097\/00008571-200104000-00005.","journal-title":"Pharmacogenetics"},{"issue":"10","key":"672_CR32","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1093\/clinchem\/48.10.1668","volume":"48","author":"RH van Schaik","year":"2002","unstructured":"van Schaik RH, van der Heiden IP, van den Anker JN, Lindemans J: CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem. 2002, 48 (10): 1668-1671.","journal-title":"Clin Chem"},{"issue":"2","key":"672_CR33","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/00008571-200302000-00005","volume":"13","author":"B Chowbay","year":"2003","unstructured":"Chowbay B, Cumaraswamy S, Cheung YB, Zhou Q, Lee EJ: Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics. 2003, 13 (2): 89-95. 10.1097\/00008571-200302000-00005.","journal-title":"Pharmacogenetics"},{"issue":"7","key":"672_CR34","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1097\/01.ASN.0000073901.94759.36","volume":"14","author":"D Anglicheau","year":"2003","unstructured":"Anglicheau D, Verstuyft C, Laurent-Puig P, Becquemont L, Schlageter MH, Cassinat B, Beaune P, Legendre C, Thervet E: Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol. 2003, 14 (7): 1889-1896. 10.1097\/01.ASN.0000073901.94759.36.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"672_CR35","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1067\/mcp.2002.126177","volume":"72","author":"Y Kurata","year":"2002","unstructured":"Kurata Y, Ieiri I, Kimura M, Morita T, Irie S, Urae A, Ohdo S, Ohtani H, Sawada Y, Higuchi S, et al: Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin Pharmacol Ther. 2002, 72 (2): 209-219. 10.1067\/mcp.2002.126177.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"672_CR36","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1046\/j.1365-2125.2003.01937.x","volume":"56","author":"AC Allabi","year":"2003","unstructured":"Allabi AC, Gala JL, Desager JP, Heusterspreute M, Horsmans Y: Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations. Br J Clin Pharmacol. 2003, 56 (6): 653-657. 10.1046\/j.1365-2125.2003.01937.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"672_CR37","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1097\/00008571-200011000-00009","volume":"10","author":"MT Tayeb","year":"2000","unstructured":"Tayeb MT, Clark C, Ameyaw MM, Haites NE, Evans DA, Tariq M, Mobarek A, Ofori-Adjei D, McLeod HL: CYP3A4 promoter variant in Saudi, Ghanaian and Scottish Caucasian populations. Pharmacogenetics. 2000, 10 (8): 753-756. 10.1097\/00008571-200011000-00009.","journal-title":"Pharmacogenetics"},{"issue":"1","key":"672_CR38","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1159\/000066695","volume":"54","author":"CM Zeigler-Johnson","year":"2002","unstructured":"Zeigler-Johnson CM, Walker AH, Mancke B, Spangler E, Jalloh M, McBride S, Deitz A, Malkowicz SB, Ofori-Adjei D, Gueye SM, et al: Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4. Hum Hered. 2002, 54 (1): 13-21. 10.1159\/000066695.","journal-title":"Hum Hered"},{"key":"672_CR39","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1471-2350-6-19","volume":"6","author":"AA Garsa","year":"2005","unstructured":"Garsa AA, McLeod HL, Marsh S: CYP3A4 and CYP3A5 genotyping by Pyrosequencing. BMC Med Genet. 2005, 6: 19-10.1186\/1471-2350-6-19.","journal-title":"BMC Med Genet"},{"issue":"2","key":"672_CR40","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00228-003-0594-2","volume":"59","author":"C Balram","year":"2003","unstructured":"Balram C, Zhou Q, Cheung YB, Lee EJ: CYP3A5*3 and *6 single nucleotide polymorphisms in three distinct Asian populations. Eur J Clin Pharmacol. 2003, 59 (2): 123-126.","journal-title":"Eur J Clin Pharmacol"},{"issue":"9","key":"672_CR41","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1097\/00008571-200112000-00005","volume":"11","author":"E Hustert","year":"2001","unstructured":"Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K, Nuessler AC, Neuhaus P, Klattig J, Eiselt R, et al: The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics. 2001, 11 (9): 773-779. 10.1097\/00008571-200112000-00005.","journal-title":"Pharmacogenetics"},{"issue":"3","key":"672_CR42","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/BF03256456","volume":"10","author":"TM Bosch","year":"2006","unstructured":"Bosch TM, Doodeman VD, Smits PH, Meijerman I, Schellens JH, Beijnen JH: Pharmacogenetic screening for polymorphisms in drug-metabolizing enzymes and drug transporters in a Dutch population. Mol Diagn Ther. 2006, 10 (3): 175-185.","journal-title":"Mol Diagn Ther"},{"issue":"4","key":"672_CR43","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/004947550303300407","volume":"33","author":"BA Boatin","year":"2003","unstructured":"Boatin BA: The current state of the Onchocerciasis Control Programme in West Africa. Trop Doct. 2003, 33 (4): 209-214.","journal-title":"Trop Doct"},{"issue":"3","key":"672_CR44","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/S0924-8579(03)00221-8","volume":"22","author":"D Kerboeuf","year":"2003","unstructured":"Kerboeuf D, Blackhall W, Kaminsky R, von Samson-Himmelstjerna G: P-glycoprotein in helminths: function and perspectives for anthelmintic treatment and reversal of resistance. Int J Antimicrob Agents. 2003, 22 (3): 332-346. 10.1016\/S0924-8579(03)00221-8.","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"672_CR45","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2165\/00003088-200140030-00002","volume":"40","author":"Y Zhang","year":"2001","unstructured":"Zhang Y, Benet LZ: The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet. 2001, 40 (3): 159-168. 10.2165\/00003088-200140030-00002.","journal-title":"Clin Pharmacokinet"},{"issue":"9300","key":"672_CR46","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/S0140-6736(02)07276-8","volume":"359","author":"J Fellay","year":"2002","unstructured":"Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, Decosterd LA, Furrer H, Opravil M, Pantaleo G, et al: Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet. 2002, 359 (9300): 30-36. 10.1016\/S0140-6736(02)07276-8.","journal-title":"Lancet"},{"issue":"3","key":"672_CR47","first-page":"653","volume":"9","author":"MT Tayeb","year":"2002","unstructured":"Tayeb MT, Clark C, Sharp L, Haites NE, Rooney PH, Murray GI, Payne SN, McLeod HL: CYP3A4 promoter variant is associated with prostate cancer risk in men with benign prostate hyperplasia. Oncol Rep. 2002, 9 (3): 653-655.","journal-title":"Oncol Rep"}],"container-title":["BMC Medical Genetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2350-11-111.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2350-11-111\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2350-11-111","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T22:25:33Z","timestamp":1740263133000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcmedgenet.biomedcentral.com\/articles\/10.1186\/1471-2350-11-111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,14]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["672"],"URL":"https:\/\/doi.org\/10.1186\/1471-2350-11-111","relation":{},"ISSN":["1471-2350"],"issn-type":[{"value":"1471-2350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7,14]]},"article-number":"111"}}